Targeted Therapy for Blood Cancer: A Personalised Approach to Treatment
Blood cancer treatment has evolved significantly over the years, moving away from traditional chemotherapy-based approaches to more precise and personalised treatments. One of the most promising advancements in cancer care is targeted therapy, which focuses on attacking cancer cells based on their unique genetic and molecular characteristics. Unlike chemotherapy, which affects both healthy and cancerous cells, targeted therapy minimises damage to normal cells and improves patient outcomes.
As targeted therapy becomes a crucial part of blood cancer treatment, it is essential for patients to have a comprehensive mediclaim policy for family that covers such advanced treatments. Since these therapies can be expensive, the right insurance plan ensures that financial constraints do not become a barrier to accessing the best medical care.
Understanding Targeted Therapy for Blood Cancer
Targeted therapy is a form of precision medicine that works by identifying specific proteins, genes, or pathways that allow cancer cells to grow and spread. The treatment halts cancer progression by blocking these targets while reducing harmful side effects. This makes it particularly effective for treating various types of blood cancers, including leukaemia, lymphoma, and multiple myeloma.
How Targeted Therapy Works
Targeted therapy is a revolutionary approach in cancer treatment that focuses on attacking specific molecules involved in cancer cell growth and survival while minimizing damage to healthy cells. Unlike traditional chemotherapy, which affects both cancerous and normal cells, targeted drugs work by interfering with the biological processes that allow cancer to thrive. These drugs can block signals that stimulate uncontrolled cell division, destroy proteins essential for tumour survival, and prevent cancer cells from developing resistance to treatment. Some targeted therapies also enhance the body’s immune response, making it more effective in identifying and destroying cancer cells. Depending on the type and stage of blood cancer, targeted therapy may be used alone or in combination with chemotherapy, immunotherapy, or stem cell transplants to improve treatment outcomes and enhance patient survival rates.
Types of Targeted Therapy for Blood Cancer
Several types of targeted therapies have been developed to treat blood cancers effectively. The most commonly used approaches include:
1. Tyrosine Kinase Inhibitors (TKIs)
Tyrosine kinases (TKIs) are enzymes that play a role in cell signalling. They allow cancer cells to grow uncontrollably, but TKIs block these signals, effectively stopping cancer cell division.
Used primarily for chronic myeloid leukaemia (CML) and some cases of acute lymphoblastic leukaemia (ALL)
Common drugs: Imatinib (Gleevec), Dasatinib, Nilotinib
Patients on TKIs often experience long-term disease control with fewer side effects compared to chemotherapy.
2. Monoclonal Antibodies
These lab-made antibodies are designed to target specific proteins in cancer cells, marking them for destruction by the immune system.
Used for lymphomas, chronic lymphocytic leukaemia (CLL), and multiple myeloma
Common drugs: Rituximab, Daratumumab, Obinutuzumab
Helps the immune system recognise and attack cancer cells more effectively.
3. Proteasome Inhibitors
Proteasomes are protein complexes that help regulate cell function. Inhibiting them disrupts cancer cell survival mechanisms, leading to cell death.
Primarily used in multiple myeloma and some lymphomas
Common drugs: Bortezomib, Carfilzomib
Often combined with other therapies to improve treatment outcomes.
4. BCL-2 Inhibitors
BCL-2 is a protein that prevents cancer cells from undergoing natural cell death (apoptosis). BCL-2 inhibitors help restore this process, allowing cancer cells to self-destruct.
Effective in chronic lymphocytic leukaemia (CLL) and certain types of lymphoma
Common drug: Venetoclax
Particularly useful for patients who do not respond well to chemotherapy.
5. Hedgehog Pathway Inhibitors
This pathway plays a role in cell growth, and its abnormal activation can lead to cancer. Hedgehog inhibitors block this pathway, preventing cancer cells from multiplying.
Used in acute myeloid leukaemia (AML)
Common drug: Glasdegib
Helps slow down the progression of aggressive blood cancers.
Benefits of Targeted Therapy in Blood Cancer Treatment
Targeted therapy has several advantages over conventional treatments, making it a preferred approach for many blood cancer patients.
1. More Effective with Fewer Side Effects
Since targeted drugs act specifically on cancer cells, they cause less damage to healthy cells, leading to fewer side effects compared to chemotherapy.
2. Improved Survival Rates
Many patients, especially those with CML and CLL, can achieve long-term remission with targeted therapy, often leading to better survival rates.
3. Can Be Taken as Oral Medication
Many targeted drugs are available in pill form, allowing patients to take them at home without frequent hospital visits.
4. Suitable for Patients Who Cannot Tolerate Chemotherapy
Older patients or those with underlying health conditions who cannot handle the harsh effects of chemotherapy can benefit from targeted therapy as a safer alternative.
5. Personalised Treatment Approach
Since targeted therapy is based on specific genetic and molecular profiles, it ensures that treatment is tailored to each individual’s cancer type and progression.
Challenges and Risks of Targeted Therapy
Despite its advantages, targeted therapy is not without challenges.
Cancer Cells Can Develop Resistance: Some patients may stop responding to targeted drugs over time, requiring combination treatments.
High Cost of Treatment: Targeted therapies are expensive, making it essential to have a mediclaim policy for family that covers these advanced treatments.
Potential Side Effects: Although milder than chemotherapy, side effects such as fatigue, skin rashes, and digestive issues can still occur.
Why is Financial Protection Essential for Targeted Therapy?
The cost of targeted therapy varies widely depending on the drug used, duration of treatment, and hospitalisation expenses. In India, targeted drug therapy can cost anywhere from ₹1 lakh to ₹5 lakh per month, making financial planning crucial for patients undergoing blood cancer treatment.
A mediclaim policy for family ensures that advanced cancer treatments, including targeted therapy, chemotherapy, and hospitalisation expenses, are covered, providing peace of mind to patients and their families.
Conclusion
Targeted therapy is revolutionizing blood cancer treatment by providing a more precise, effective, and patient-friendly alternative to traditional chemotherapy. With continuous advancements in medical research, newer targeted therapies are emerging, significantly improving survival rates and enhancing the quality of life for cancer patients. However, the cost of these advanced treatments can be overwhelming, making comprehensive health insurance plans a necessity.
With Niva Bupa Health Insurance, patients can access cutting-edge cancer treatments without financial stress. Our plans provide extensive coverage for hospitalization, chemotherapy, targeted drug therapy, and other essential treatments, ensuring that financial constraints do not hinder life-saving care. As personalized medicine continues to evolve, having the right health insurance plan will be crucial in securing access to the best possible cancer care, allowing patients to focus on their recovery with peace of mind.
